Adverse Events from Drug Therapy for Human Immunodeficiency Virus Disease
Authors:
- Ilana FortgangIFIlana Fortgang
- Jeanne KerulyJKJeanne Keruly
- Richard E. ChaissonRCRichard E. Chaisson
Open Access
- 1 July 1996
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 101 (1) , 34-40
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Rates and Risk Factors for Adverse Events Associated with Didanosine in the Expanded Access ProgramClinical Infectious Diseases, 1994
- Efficacy of zidovudine treatment in homosexual men with AIDS-related complexAIDS, 1994
- Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban CommunityNew England Journal of Medicine, 1994
- Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patientsAIDS, 1994
- Clinical and Laboratory Markers of Hypersensitivity to Trimethoprim-Sulfamethoxazole in Patients with Pneumocystis carinii Pneumonia and AIDSThe Journal of Infectious Diseases, 1993
- Interactions and Toxicities of Drugs Used in Patients with AIDSClinical Infectious Diseases, 1992
- Adverse reactions to co-trimoxazole in HIV infectionThe Lancet, 1991
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987